{"id":"W2105167551","doi":"10.1016/s0140-6736(11)61649-8","title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","year":2011,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":741,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; McGill University; University of British Columbia","funders":"F. Hoffmann-La Roche; IC Design Education Center; Biogen Idec; Biogen","keywords":"Ocrelizumab; Medicine; Placebo; Interferon beta-1a; Multiple sclerosis; Clinical endpoint; Internal medicine; Population; Clinical trial; Immunology; Rituximab; Interferon beta; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1512711031892404,"score_gpt":0.3369648857764854,"score_spread":0.185693782587245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}